• Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma

    Apr 1, 2022, 00:00

  • US Food and Drug Administration Analysis of Patient-Reported Diarrhea and Its Impact on Function and Quality of Life in Patients Receiving Treatment for Breast Cancer

    Apr 1, 2022, 00:00

  • Copyright/Subscription

    Apr 1, 2022, 00:00

  • Estimating and Extrapolating Survival Using a State-Transition Modeling Approach: A Practical Application in Multiple Myeloma

    Apr 1, 2022, 00:00

  • Parametric Survival Extrapolation of Early Survival Data in Economic Analyses: A Comparison of Projected Versus Observed Updated Survival

    Apr 1, 2022, 00:00

  • Barriers and Expectations for Patients in Post-Osteoporotic Fracture Care in France: The EFFEL Study

    Apr 1, 2022, 00:00

  • A Review of Patient-Reported Outcome Labeling of FDA-Approved New Drugs (2016-2020): Counts, Categories, and Comprehensibility [Editor's Choice]

    Apr 1, 2022, 00:00

  • Expanding the Scope of Value for Economic Evaluation: The EQ-HWB [Editor's choice]

    Apr 1, 2022, 00:00

  • Generation, Selection, and Face Validation of Items for a New Generic Measure of Quality of Life: The EQ-HWB

    Apr 1, 2022, 00:00

  • Developing a New Generic Health and Wellbeing Measure: Psychometric Survey Results for the EQ-HWB

    Apr 1, 2022, 00:00

  • Rasch Analysis of the Michigan Hand Questionnaire

    Apr 1, 2022, 00:00

  • Table of Contents

    Apr 1, 2022, 00:00

  • Variation in Model-Based Economic Evaluations of Low-Dose Computed Tomography Screening for Lung Cancer: A Methodological Review

    Apr 1, 2022, 00:00

  • A Comparison of a Preliminary Version of the EQ-HWB Short and the 5-Level Version EQ-5D

    Apr 1, 2022, 00:00

  • Cost and Quality of Life Outcomes of the STepped Exercise Program for Patients With Knee OsteoArthritis Trial

    Apr 1, 2022, 00:00

  • The History and Future of the “ISPOR Value Flower”: Addressing Limitations of Conventional Cost-Effectiveness Analysis [Editor's Choice]

    Apr 1, 2022, 00:00

  • The Development of a New International Generic Measure (EQ-HWB): Face Validity and Psychometric Stages in Argentina

    Apr 1, 2022, 00:00

  • The Role of Indication-Based Pricing in Future Pricing and Reimbursement Policies: A Systematic Review

    Apr 1, 2022, 00:00

  • The EQ-HWB: Overview of the Development of a Measure of Health and Wellbeing and Key Results

    Apr 1, 2022, 00:00

  • Qualitative Review on Domains of Quality of Life Important for Patients, Social Care Users, and Informal Carers to Inform the Development of the EQ-HWB

    Apr 1, 2022, 00:00

  • Opportunities and Barriers to the Development and Use of Open Source Health Economic Models: A Survey [Editor's Choice]

    Apr 1, 2022, 00:00

  • Cost-Effectiveness Analysis of SAPIEN 3 Transcatheter Aortic Valve Implantation Procedure Compared With Surgery in Patients With Severe Aortic Stenosis at Low Risk of Surgical Mortality in France

    Apr 1, 2022, 00:00

  • Medicaid Expansion’s Impact on Emergency Department Use by State and Payer [Editor's Choice]

    Apr 1, 2022, 00:00

  • Editorial Board

    Mar 30, 2022, 09:26

  • Incentivizing Prescription Drug Switching to Reduce Patient and Health Plan Spending: A Microsimulation Model

    Mar 1, 2022, 00:00

  • Performance of the UK Prospective Diabetes Study Outcomes Model 2 in a Contemporary UK Type 2 Diabetes Trial Cohort

    Mar 1, 2022, 00:00

  • Economic Evaluation of National Patient Blood Management Clinical Guidelines in Cardiac Surgery

    Mar 1, 2022, 00:00

  • Copyright/Subscription

    Mar 1, 2022, 00:00

  • Assessing the Economic Value of Clinical Artificial Intelligence: Challenges and Opportunities [Editor's Choice]

    Mar 1, 2022, 00:00

  • Systematic Review of Health Economic Evaluations Focused on Artificial Intelligence in Healthcare: The Tortoise and the Cheetah [Editor's Choice]

    Mar 1, 2022, 00:00

  • Assessing Payers’ Preferences for Real-World Evidence in the United States: A Discrete Choice Experiment [Editor's Choice]

    Mar 1, 2022, 00:00

  • Reviewer Acknowledgment

    Mar 1, 2022, 00:00

  • A Framework for Using Real-World Data and Health Outcomes Modeling to Evaluate Machine Learning–Based Risk Prediction Models

    Mar 1, 2022, 00:00

  • Fulfilling the Promise of Artificial Intelligence in the Health Sector: Let’s Get Real

    Mar 1, 2022, 00:00

  • CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis

    Mar 1, 2022, 00:00

  • Do People Favor Artificial Intelligence Over Physicians? A Survey Among the General Population and Their View on Artificial Intelligence in Medicine

    Mar 1, 2022, 00:00

  • The Potential Cost-Effectiveness of a Machine Learning Tool That Can Prevent Untimely Intensive Care Unit Discharge

    Mar 1, 2022, 00:00

  • The Use of Cost-Effectiveness Thresholds for Evaluating Health Interventions in Low- and Middle-Income Countries From 2015 to 2020: A Review

    Mar 1, 2022, 00:00

  • Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England [Editor's Choice]

    Mar 1, 2022, 00:00

  • The Value of Artificial Intelligence for Healthcare Decision Making—Lessons Learned [Editor's Choice]

    Mar 1, 2022, 00:00

  • Table of Contents

    Mar 1, 2022, 00:00

  • Estimating the Economic Value of CDX2 as a Predictive Biomarker to Guide Treatment Decisions in Stage II Colon Cancer

    Mar 1, 2022, 00:00

  • Investigating 5-Level EQ-5D (EQ-5D-5L) Values Based on Preferences of Patients With Heart Disease

    Mar 1, 2022, 00:00

  • Genetic-Guided Pharmacotherapy for Atrial Fibrillation: A Systematic and Critical Review of Economic Evaluations

    Mar 1, 2022, 00:00

  • Does Every Minute Really Count? Road Time as an Indicator for the Economic Value of Emergency Medical Services

    Mar 1, 2022, 00:00

  • Editorial Board

    Feb 28, 2022, 09:01

  • Approaches for Enhanced Extrapolation of Long-Term Survival Outcomes Using Electronic Health Records of Patients With Cancer

    Feb 1, 2022, 00:00

  • Copyright/Subscription

    Feb 1, 2022, 00:00

  • Estimating and Comparing Health and Financial Risk Protection Outcomes in Economic Evaluations

    Feb 1, 2022, 00:00

  • Is Ethylene-Vinyl Alcohol Copolymer Really as Cost-Effective as N-Butyl Cyanoacrylate Glue for Transcatheter Arterial Embolization of Gastrointestinal Bleeding in the United States and Outside?

    Feb 1, 2022, 00:00

  • Health State Utilities for Sickle Cell Disease: A Catalog Prepared From a Systematic Review

    Feb 1, 2022, 00:00

  • What Constitutes Preferred Long-Term Care Provided in Residential Aged Care Facilities? An Empirical Comparison of the Preferences of the General Population, Residents, and Family Members [Editor's Choice]

    Feb 1, 2022, 00:00

  • A Comparison of the Cost-Effectiveness of Lifestyle Interventions in Pregnancy

    Feb 1, 2022, 00:00

  • Heterogeneity in Radiotherapeutic Parameter Assumptions in Cost-Effectiveness Analyses in Prostate Cancer: A Call for Uniformity [Editor's Choice]

    Feb 1, 2022, 00:00

  • What Is Value in Health and Healthcare? A Systematic Literature Review of Value Assessment Frameworks [Editor's Choice]

    Feb 1, 2022, 00:00

  • Do You Recall?: Results From a Within-Person Recall Study of the Patient-Reported Outcomes Measurement Information System (PROMIS) Short Form v2.0 – Physical Function 8c

    Feb 1, 2022, 00:00

  • Using Virtual Reality Exposure Therapy in Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Feb 1, 2022, 00:00

  • Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50%

    Feb 1, 2022, 00:00

  • How Can We Make More Rapid Progress in the Leveraging of Real-World Evidence by Regulatory Decision Makers? [Editor's Choice]

    Feb 1, 2022, 00:00

  • Cost-Effectiveness in Perioperative Care: Application of Markov Modeling to Pathways of Perioperative Care

    Feb 1, 2022, 00:00

  • Prioritizing Healthcare Interventions: A Comparison of Multicriteria Decision Analysis and Cost-Effectiveness Analysis [Editor's Choice]

    Feb 1, 2022, 00:00

  • Do Profit Margins of Pharmaceuticals Influence Reimbursement Decisions? A Discrete Choice Experiment Among Dutch Healthcare Decision Makers

    Feb 1, 2022, 00:00

  • Impact of Adding Oseltamivir to Usual Care on Quality-Adjusted Life-Years During Influenza-Like Illness

    Feb 1, 2022, 00:00

  • Table of Contents

    Feb 1, 2022, 00:00

  • Time Costs and Out-of-Pocket Costs in Patients With Chronic Hepatitis C in a Publicly Funded Health System

    Feb 1, 2022, 00:00

  • Cost-Effectiveness of Posthospital Management of Acute Coronary Syndrome: A Real-World Investigation From Italy

    Feb 1, 2022, 00:00

  • Editorial Board

    Jan 27, 2022, 09:58

  • Editorial Board

    Jan 3, 2022, 16:02

  • POSC180 Epidemiological Disease Burden of Left Ventricular Failure Based on Routinely Collected Health Insurance Claims Data

    Jan 1, 2022, 00:00

  • POSB306 Generative Adversarial Networks to Generate Synthetic Controls: A Real-World Data Example

    Jan 1, 2022, 00:00

  • POSC95 The Economic Burden of Lung Cancer in China: A Systematic Literature Review

    Jan 1, 2022, 00:00

  • POSC212 A Most-Similar Case Analysis of Gene Expression Test Reimbursement Assessment in Europe

    Jan 1, 2022, 00:00

  • POSA151 Cost-of-Illness in Adults with Diabetes Mellitus Type I in the Russian Federation

    Jan 1, 2022, 00:00

  • POSA89 Annual Health Insurance Treatment Cost of Non-Insulin-Dependent Diabetes with Peripheral Circulatory Complications Based on Routinely Collected Financing Data

    Jan 1, 2022, 00:00

  • POSB205 Framework for Implementing Cost-Effectiveness Thresholds in Egypt

    Jan 1, 2022, 00:00

  • P28 Impact of COVID-19 on Mental Health in Young Adults in the United States

    Jan 1, 2022, 00:00

  • POSA327 Development of Conceptual Models Investigating the Health-Related Quality of Life (HRQOL) Impacts of Malignant Pleural Mesothelioma (MPM)

    Jan 1, 2022, 00:00

  • POSA373 Evaluation of Ehealth Literacy Measurement Tools and Its Associated Factors: A Systematic Review and Meta-Analysis

    Jan 1, 2022, 00:00

  • POSC366 Validity of the EQ-5D-3L and EQ-5D-5L in Advanced Melanoma

    Jan 1, 2022, 00:00

  • POSB312 Markov Models for Chronic Kidney Disease in Type 2 Diabetes: Differences and Commonalities in Model Structures and Modeled Health States

    Jan 1, 2022, 00:00

  • POSA33 Matching-Adjusted Indirect Comparisons of Avapritinib Versus Midostaurin Among Patients with Advanced Systemic Mastocytosis

    Jan 1, 2022, 00:00

  • P72 Prediction of the Prevalence of Resistance of Acinetobacter Baumannii to Colistin in the City of Valencia (Spain) with a New Agent-Based Model

    Jan 1, 2022, 00:00

  • POSC376 Speak up Your Pain: Patient Care Course in Chronic Pain

    Jan 1, 2022, 00:00

  • POSA303 Influence of Treatment Effect on Parameters in Fractional Polynomials for Network Meta-Analyses

    Jan 1, 2022, 00:00

  • POSC274 Does Conditional Marketing Authorisation Speed Up Patient Access?

    Jan 1, 2022, 00:00

  • POSC391 The Landscape of Non-Melanoma Skin Cancer in Portugal

    Jan 1, 2022, 00:00

  • POSB332 Comparison of Frozen Shoulder Syndrome Treatment Results Using Traditional and Functional Fasia Training Methods

    Jan 1, 2022, 00:00

  • POSA415 Association of an Adenosine A2A Antagonist Istradefylline on the Treatment Paradigm of Levodopa for Patients with Parkinson’s Disease: Real-World Evidence from a Nationwide Japanese Database over 10 Years (2008-2019)

    Jan 1, 2022, 00:00

  • POSB7 Adverse Events Associated with Antidepressants: A Systematic Literature Review and Network Meta-Analysis

    Jan 1, 2022, 00:00

  • POSB412 Direct and Indirect Costs Associated with Chronic Lymphocytic Leukemia in Slovakia: 5 Years' Overview

    Jan 1, 2022, 00:00

  • POSC381 Derivation of Interpretation Thresholds for the SF-36V2® Health Survey (SF-36V2) in Rheumatoid Arthritis

    Jan 1, 2022, 00:00

  • POSA216 Biosimilar Assessment Frameworks and Policy Shifts in the EU in the Post-COVID Context

    Jan 1, 2022, 00:00

  • POSA245 Workflow Mapping of the Paediatric Hexavalent Immunisation Process in the United Kingdom (UK) to Inform Feasibility of a Time and Motion Study

    Jan 1, 2022, 00:00

  • POSA320 Development of a Decision Algorithm for Fractional Polynomial (FP) Model Selection in Network Meta-Analysis (NMA): Why Statistical Fit Criteria Alone Is Not Enough

    Jan 1, 2022, 00:00

  • POSB103 COVID-19 Positive Patients Hospital Management in the Italian Setting: The Economic Impact

    Jan 1, 2022, 00:00

  • POSA406 Caregiver Absence Payments and Lost Time Due to Sick Leave, Long- and Short-Term Disability and Workers' Compensation for Employees Whose Spouses Have Mental Disorders in the United States

    Jan 1, 2022, 00:00

  • Systematic Review of Cost-Effectiveness Models in Prostate Cancer: Exploring New Developments in Testing and Diagnosis

    Jan 1, 2022, 00:00

  • Patterns of Medical Care Cost by Service Type for Patients With Recurrent and De Novo Advanced Cancer

    Jan 1, 2022, 00:00

  • POSC178 Identification of Heart Failure Subtypes within Patient Records: An Analysis of Linked Primary and Secondary Care Data in England

    Jan 1, 2022, 00:00

  • POSC58 Budget Impact of Pembrolizumab for Untreated or Unresectable Head and Neck Cancer in Ireland

    Jan 1, 2022, 00:00

  • POSA383 Identification of Risk Factors Associated with COVID-19 Hospitalization

    Jan 1, 2022, 00:00

  • POSA256 Single-Photon Emission Computed Tomography Combined with Computed Tomography (SPECT/CT) to Detect Sentinel Lymph Nodes in Breast Cancer

    Jan 1, 2022, 00:00

  • POSA268 Economic and Humanistic Impact of Vasospasm-Related Complications Following Aneurysmal Subarachnoid Hemorrhage; Results of a Systematic Literature Review

    Jan 1, 2022, 00:00

  • POSC52 Cost-Effectiveness of Atezolizumab in Association with Bevacizumab for Patients with Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Using a French Real-World Evidence Database

    Jan 1, 2022, 00:00

  • POSA173 Onset of Stroke in Patients with Post-COVID-19 Syndrome Following Hospitalisation for Severe COVID-19 Infection: A Systematic Literature Review

    Jan 1, 2022, 00:00

  • POSA349 Unmet Needs for Insomnia Patients - Humanistic Burden in Europe

    Jan 1, 2022, 00:00

  • POSA130 Events Avoided and Cost Savings Associated with Ferric Carboxymaltose Treatment of Iron Deficiency in Patients with Acute Heart Failure with Reduced Ejection Fraction from the Perspective of Healthcare Payers in Switzerland

    Jan 1, 2022, 00:00

  • POSB267 Influence of Real-World Evidence to Support Single Arm Trials Submitted to NICE for Orphan Oncology Products

    Jan 1, 2022, 00:00

  • POSA247 Impact of Transferring the Dispensing of Hospital-Only Medicines to Community Pharmacies during COVID-19 Pandemic: A Single-Arm, Before-and-After Study

    Jan 1, 2022, 00:00

  • POSC182 Epidemiological Disease Burden of Mental and Behavioural Disorders Due to Use of Alcohol Based on Routinely Collected Health Insurance Claims Data

    Jan 1, 2022, 00:00

  • POSC48 Cost-Effectiveness Analysis of Ferric Carboxymaltose Versus Iron Sucrose for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease in Spain

    Jan 1, 2022, 00:00

  • POSB344 A Qualitative Study of the Symptoms and Health-Related Quality of Life Impact Experienced by Patients Diagnosed with NASH (Non-Alcoholic Steatohepatitis)

    Jan 1, 2022, 00:00

  • POSC184 Targeted Literature Review Linking Wet Age-Related Macular Degeneration Real-World Evidence to Healthcare System Capacity and Spending

    Jan 1, 2022, 00:00

  • POSC152 Cost-Effectiveness Analysis of Follitropin ALFA Product (GONAL-F) Compared to Its Biosimilars Based on Meta-Analysis of Randomized Controlled Trials

    Jan 1, 2022, 00:00

  • P16 Recent Estimates of Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) in the US (2010-2020)

    Jan 1, 2022, 00:00

  • POSC223 Realising the Full Potential of Benefit-Sharing Programs Established to Promote the Cost-Effective Prescribing of Biologics: A European Comparative Analysis of Implementation Challenges

    Jan 1, 2022, 00:00

  • POSC106 Budget Impact Analysis of Including Sacubitril/Valsartan in the National Formulary for the Treatment of Heart Failure with Reduced Ejection Fraction (HFREF) in Thailand

    Jan 1, 2022, 00:00

  • POSC74 Considerations for Mental Health Effects in Health Economic Analyses

    Jan 1, 2022, 00:00

  • POSB73 Cost-Minimization Analysis for Subcutaneous Daratumumab in the Treatment of Multiple Myeloma in Italy

    Jan 1, 2022, 00:00

  • POSB109 Cost-Effectiveness and Cost-Utility Analyses of Polatuzumab Vedotin with Bendamustine and Rituximab vs. Bendamustine and Rituximab for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

    Jan 1, 2022, 00:00

  • POSC410 Healthcare Utilization, Mortality, and Cost of Sepsis Post-Ureteroscopy Among a Medicare Population

    Jan 1, 2022, 00:00

  • POSB271 Is NICE Becoming More Efficient in the Duration of the Highly-Specialised Technologies (HST) Process?

    Jan 1, 2022, 00:00

  • POSA377 Time Trade-Off Health Utility Values for Depression: A Systematic Review

    Jan 1, 2022, 00:00

  • POSC33 Value Contribution of Filgotinib for the Treatment of Moderate to Severe Rheumatoid Arthritis Using Multi-Criteria Decision Analysis (MCDA)

    Jan 1, 2022, 00:00

  • POSA35 Lifetime Survival Estimates for Nivolumab+Ipilimumab and Sunitinib in Previously Untreated Patients with Advanced/Metastatic Intermediate- or Poor (I/P)-Risk Renal Cell Carcinoma (1L ARCC) Based on 5-Year Minimum Follow-up Data from ...

    Jan 1, 2022, 00:00

  • POSA5 Comparison of Healthcare Resource Utilization Among Hospitalized Patients with Acquired Thrombotic Thrombocytopenic Purpura Treated with or without Caplacizumab: A French Hospital Database (PMSI) Analysis

    Jan 1, 2022, 00:00

  • POSC258 Acceptance of Progression-Free Survival 2 (PFS2) By EU5 and Canadian Health Authorities for Cancer Drug Reimbursement

    Jan 1, 2022, 00:00

  • POSA250 Impact of Iron-Deficiency Anaemia on Disease Progression in Patients with Inflammatory Bowel Disease: A Real-World Data Analysis in Italy

    Jan 1, 2022, 00:00

  • POSC353 Quality of Life in Chronic Kidney Disease (CKD): Results from a Systematic Review of CKD Models for Type 2 Diabetes

    Jan 1, 2022, 00:00

  • POSC84 Annual Health Insurance Treatment Cost of Hip Osteoarthritis Based on Routinely Collected Financing Data

    Jan 1, 2022, 00:00

  • POSB173 Likelihood of UK Early Access Products to Receive a Positive NICE Recommendation

    Jan 1, 2022, 00:00

  • POSA150 Cost-Effectiveness Analysis of First-Line (1L) Systemic Treatments in Advanced Renal Cell Carcinoma (aRCC) in France

    Jan 1, 2022, 00:00

  • POSC401 Hospitalization Cost and Health Care Utilization of Women's Cancer Surgery: A Real World Evidence Study in Korea

    Jan 1, 2022, 00:00

  • POSC73 Economic Burden of Transport Accidents, Falls at Home and in Public Places Due to Untreated Chronic Insomnia (UCI) in the United-States (US), Estimated By the Population Attributable Fraction (PAF) Method

    Jan 1, 2022, 00:00

  • POSB284 The Impact of Burden of Diseases on the Rate of Innovation in Portugal

    Jan 1, 2022, 00:00

  • POSB399 Systematic Identification of Pharmacological Inefficiencies By a Value-Based Patient Drug Safety Program

    Jan 1, 2022, 00:00

  • POSB397 Benefits of Homeopathic Complementary Treatment in Breast Cancer Patients: A Retrospective Cohort Study Based on the French Nationwide Healthcare Database (SNDS)

    Jan 1, 2022, 00:00

  • POSC310 Assessment of Anthelmintics Consumption in Ukraine in Comparison with Other Countries of the World

    Jan 1, 2022, 00:00

  • POSC129 Economic Burden of Metastatic Breast Cancer in Greece

    Jan 1, 2022, 00:00

  • POSB277 Evaluation of Therapies Launching within a Space with No Approved Standard of Care

    Jan 1, 2022, 00:00

  • POSC82 Health Economic Model for Estimating the Direct Cost Impact of Adopting an Antimicrobial Vascular Access Site Dressing in Patients Receiving Haemodialysis Via Tunnelled Central Venous Catheter in the UK

    Jan 1, 2022, 00:00

  • POSB386 Predictors of Good Perceived Health Status Among United States Older Adults with Self-Reported Pain

    Jan 1, 2022, 00:00

  • POSA427 Assessment of the Impact of Fibrodysplasia Ossificans Progressiva on Quality of Life for Patients and their Families Using an International Burden of Illness Survey

    Jan 1, 2022, 00:00

  • POSC408 Demographic Characteristics and Initial Diagnostic Staging of Patients with Non-Small Cell Lung Cancer across Large Community Health Systems in the US

    Jan 1, 2022, 00:00

  • A Perspective on Suitability of a Cost-Based Pricing Methodology for Repurposed Orphan Medicines: A Consideration of the Overall Value Proposition

    Jan 1, 2022, 00:00

  • POSB225 Differences and Similarities in the Methods: of Pricing of Prescription Drugs in Bulgaria, France, Germany, Belgium, and the UK: A Comparative Analysis

    Jan 1, 2022, 00:00

  • POSB227 The Frequency of Statin Use in German Patients with Ulcerative Colitis: A Cross-Sectional Analysis of Prevalent Cases Using a Large Retrospective Claims Database

    Jan 1, 2022, 00:00

  • Methods for Decision Modelling and Economic Evaluation

    Jan 1, 2022, 00:00

  • POSC71 Economic Evaluations of Digital Health Interventions for the Management of Musculoskeletal Disorders: A Systematic Review

    Jan 1, 2022, 00:00

  • POSB108 Cost-Effectiveness and Cost-Utility Analyses of Atezolizumab-Based Therapy in Patients with Advanced or Unresectable Hepatocellular Carcinoma in Italy

    Jan 1, 2022, 00:00

  • POSB222 Can Gene Therapy Prices Remain the Same? What We Have Learned from the COVID-19 Vaccines

    Jan 1, 2022, 00:00

  • P8 New Onset Cardiovascular Disease in Australia by Socioeconomic Groups: A Modelling Study

    Jan 1, 2022, 00:00

  • POSB411 Absence Time and Payments Due to Sick Leave, Long- and Short-Term Disability and Workers' Compensation for Employees with Circulatory Disorders in the United States

    Jan 1, 2022, 00:00

  • POSA232 Evaluating Health Outcomes of Participants Enrolled in Program of All Inclusive Care for the Elderly (PACE) and Elderly Participants Enrolled in Other Care Giving Programs: A Scoping Review

    Jan 1, 2022, 00:00

  • P68 Cardiovascular Events and Mortality in Type-2 Diabetic Patients under Second-Line Treatment with Hypoglycemic Agents: An Italian Real-World Study

    Jan 1, 2022, 00:00

  • POSA299 Impact of Implementing Difference Method for Sampling Ordered Parameter in Probabilistic Sensitivity Analysis (PSA) on Cost Effectiveness (CE) Model Outcome

    Jan 1, 2022, 00:00

  • POSC377 Twelve-Month Follow up of Ixekizumab in the Badbir Registry: Baseline Demographics, Drug Survival and Effectiveness in Biologic-Naïve Versus Biologic-Experienced Patients with Psoriasis

    Jan 1, 2022, 00:00

  • POSB19 Matching-Adjusted Indirect Comparison of Trastuzumab Deruxtecan vs. Eribulin, Capecitabine, and Vinorelbine for Treating Human Epidermal Growth Factor Receptor 2-Positive Unresectable or Metastatic Breast Cancer after Two or More Ant ...

    Jan 1, 2022, 00:00

  • POSB43 Budget Impact Analysis of Venetoclax for Management of Acute Myeloid Leukemia from the Perspective of the Social Security and the Private Sector in Argentina

    Jan 1, 2022, 00:00

  • POSC352 A Qualitative Patient Experience Study of Eteplirsen Treatment for Duchenne Muscular Dystrophy

    Jan 1, 2022, 00:00

  • POSA28 Reductions in Migraine and Headache Days After Initiating Fremanezumab for Patients with Migraine and Prior Use of Another Monoclonal Antibody Targeting the CGRP Pathway in a US Real-World Setting

    Jan 1, 2022, 00:00

  • POSC275 Impact on Bluebird's Withdrawal from the German Market on Funding for Gene Therapies

    Jan 1, 2022, 00:00

  • Varying Willingness to Pay Based on Severity of Illness: Impact on Health Technology Assessment Outcomes of Inpatient and Outpatient Drug Therapies in The Netherlands [Editor's Choice]

    Jan 1, 2022, 00:00

  • POSB53 Healthcare Resource Utilization (HCRU) and Cost Studies in Patients Receiving First-Line (1L) Therapy for Advanced or Metastatic Urothelial Carcinoma (MUC): A Systematic Literature Review (SLR)

    Jan 1, 2022, 00:00

  • POSC362 Loss of Functionality and Low Scores on Quality-of-Life Scales in Obese and Non-Obese Sarcopenic Patients with Head and Neck Cancer: Cross-Sectional Study Based on Real Data World

    Jan 1, 2022, 00:00

  • POSA310 Artificial Intelligence Applied on Administrative Big Data to Predict the Severity of SARS-COV-2 Infection

    Jan 1, 2022, 00:00

  • POSC358 Patient Perceptions of Simplicity and Complexity of Treatment for Type 2 Diabetes

    Jan 1, 2022, 00:00

  • POSB163 Cost-Effectiveness Analysis of Baloxavir Barboxil As Seasonal Influenza Treatment Compared to Oseltamivir in China

    Jan 1, 2022, 00:00

  • POSB415 Predicting Factors of Complicated Ureteral Stent Removal in Patients with Kidney Stone in the United States

    Jan 1, 2022, 00:00

  • POSC379 Assessment of Pattern of Poisoning Cases in a Tertiary Care Hospital

    Jan 1, 2022, 00:00

  • POSA135 Cost-Effectiveness of Pharmacist-LED Care Versus Usual Care in Type 2 Diabetic Jordanians: A Markov Modeling of Cardiovascular Diseases Prevention

    Jan 1, 2022, 00:00

  • POSC49 The Cost-Effectiveness of Brentuximab Vedotin in Frontline Systemic Anaplastic Large Cell Lymphoma in France

    Jan 1, 2022, 00:00

  • Table of Contents

    Jan 1, 2022, 00:00

  • POSA80 Natalizumab Utilization in Terms of Dosing Interval and Costs: A 2015-2019 Population-Based Study

    Jan 1, 2022, 00:00

  • POSC32 Attainment of Low-Density Lipoprotein Cholesterol Targets in Statin Treated Patients: Real-World Evidence from Australian Primary Care

    Jan 1, 2022, 00:00

  • POSB150 Survival Modeling Using Partitioned Survival and Semi-Markov Approaches: A Case Study in Extensive Stage Small Cell Lung Cancer

    Jan 1, 2022, 00:00

  • POSB248 Medication Management Practices for Non-Communicable Diseases during the Second Wave of the COVID-19 Pandemic: A Snapshot of the European Situation

    Jan 1, 2022, 00:00

  • POSC303 Comparative Effectiveness of Integrative Medicine for Treatment of Idiopathic Short Stature in Children: A Systematic Review and Network Meta-Analysis

    Jan 1, 2022, 00:00

  • POSC96 Budget Impact Analysis for Introduction of Cladribine Tablets As a Treatment for High Disease Active Relapsing Multiple Sclerosis in UAE

    Jan 1, 2022, 00:00

  • POSB278 Modernising the Clinical Trial: A Shift to Decentralised Trials Driven By Advances in Technology and Catalysed By the COVID-19 Pandemic

    Jan 1, 2022, 00:00

  • POSA308 A Comparison of STC and Maic Under Misspecification of the Treatment Effect and Effect-Modifier Relationship

    Jan 1, 2022, 00:00

  • POSC29 Clinical Outcomes of Diagnosis and On-Time Treatment of Acquired Thrombotic Thrombocytopenic Purpura

    Jan 1, 2022, 00:00

  • POSC159 Identification of Appropriate Stroke Event and Management Costs in Atrial Fibrillation

    Jan 1, 2022, 00:00

  • POSC80 The Costs of Hemophilia A in Algeria: The First Cross-Sectional, Multicenter Cost-of-Illness Study

    Jan 1, 2022, 00:00

  • POSA203 Assessment of Socio-Demographic Profiles of the Poisoning Cases in a Tertiary Care Hospital

    Jan 1, 2022, 00:00

  • POSB380 General Population Reference Values for the Promis Global Health in Hungary

    Jan 1, 2022, 00:00

  • POSC291 Acceleration of Digital Health Technologies in Value-Based Payment Systems

    Jan 1, 2022, 00:00

  • POSC104 Determining Cost Data for Fertility Treatment in a Spanish Setting

    Jan 1, 2022, 00:00

  • POSC108 Estimated Hospitalization-Related Costs with Oral Azacitidine (ORAL-AZA) vs. Placebo for Remission Maintenance in Patients with Acute Myeloid Leukemia (AML) in Sweden and Norway

    Jan 1, 2022, 00:00

  • P63 Impact of COVID-19 on Health-Related Quality-of-Life in the United States, Sweden and Norway: A Cross-Country Comparison Using a Panel Survey

    Jan 1, 2022, 00:00

  • POSA48 Economic Evaluation of Extending the Danish Age-Based Pneumococcal Polysaccharide Vaccination Programme to Include Individuals Aged 50-54 and 55-59

    Jan 1, 2022, 00:00

  • POSC256 Application of Progression-Free Survival As Surrogate Endpoint for Overall Survival in Nice Reviews of Advanced Breast Cancer Drugs

    Jan 1, 2022, 00:00

  • POSA384 Identification of Complications Associated with COVID-19 Infection from Claims Data

    Jan 1, 2022, 00:00

  • POSB57 Budget Impact Analysis of XprESS to Treat Sinus and Eustachian Tube Dysfunction in Spain: Positive Impact on the Care Pathway with Reduced Costs and Increased Hospital Capacity

    Jan 1, 2022, 00:00

  • POSA279 The Impact of the COVID-19 Pandemic on the MHRA’s Early Access to Medicines Scheme

    Jan 1, 2022, 00:00

  • POSA235 Immune Checkpoint Inhibitors (ICI) Infusion at Home for Cancer Patients: An Analysis of the French National Hospital Database (PMSI)

    Jan 1, 2022, 00:00

  • POSC164 Cost-of-Disease in Heart Failure in Turkey: A Delphi Panel Based Analysis of Direct Costs

    Jan 1, 2022, 00:00

  • POSC145 Waste Calculator to Improve Costs of Use of Imiglucerase in Colombia and Peru

    Jan 1, 2022, 00:00

  • POSA38 Cost-Effectiveness Analysis of for Insulin Degludec (TRESIBA®) vs. Insulin Glargine U300 (TOUJEO®) in Algerian Setting

    Jan 1, 2022, 00:00

  • POSB184 Hospital Incidence, Mortality and Costs of Alzheimer's Disease in Spain: A Retrospective Multicenter Study

    Jan 1, 2022, 00:00

  • POSA170 Prevalence of Elevated Lipoprotein(A) Among Atherosclerotic Cardiovascular Disease Patients with Lipoprotein(A) Measurements: Evidence from a Systematic Literature Review

    Jan 1, 2022, 00:00

  • P48 Joint Modelling Measurable Target Lesions, EQ5D/Utility and Overall Survival: Do We Still Need Partitioned Survival Models?

    Jan 1, 2022, 00:00

  • POSA243 Approaches to Immune Checkpoint Inhibitor (ICI) First-Line Maintenance Therapy (1L-MT) in Unresectable Locally Advanced (LA) or Metastatic Urothelial Cancer (mUC) in France, Germany, Italy, Spain, and the UK (EU5)

    Jan 1, 2022, 00:00

  • POSA16 An Umbrella Review on the Effectiveness of Systemic Treatments for the Management of Advanced Hepatocellular Carcinoma

    Jan 1, 2022, 00:00

  • Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations

    Jan 1, 2022, 00:00

  • POSA145 Budget Impact of Zanubrutinib to Treat Relapsed or Refractory Marginal Zone Lymphoma from a Payer Perspective in the United States

    Jan 1, 2022, 00:00

  • POSC413 A Systematic Review of Real-World Clinical Practice Data in COVID-19: Non-Interventional Studies

    Jan 1, 2022, 00:00

  • POSA119 Medicaid Cost Analysis in Patients with X-Linked Myotubular Myopathy: A Retrospective Longitudinal Study

    Jan 1, 2022, 00:00

  • POSB138 Medication Adherence Impacts Lost Time, Productivity Costs and Emergency Room Visits in Employees with Diabetes

    Jan 1, 2022, 00:00

  • POSB349 Work Productivity and Activity Impairment of Huntington's Disease Patients By Disease Stage in the US and EU5: Evidence from the Huntington's Disease Burden of Illness Study (HDBOI)

    Jan 1, 2022, 00:00

  • POSA410 Cancer Subtypes and Systemic Antineoplastic Treatment Utilization Among Patients with Advanced Breast Cancer Across Large Community Health Systems in the US

    Jan 1, 2022, 00:00

  • POSC107 Long Term Outcomes for Patients with Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency: A Modelling Study Exploring the Benefit of Gene Therapy

    Jan 1, 2022, 00:00

  • POSB394 Comparison of Healthcare Utilization Patterns between Intrathecal Drug Delivery Systems and Conventional Medical Management in the Treatment of Chronic Pain: Retrospective Study with Claims Datasets

    Jan 1, 2022, 00:00

  • POSC294 The Environmental Impact of the First Pass Effect in Mechanical Thrombectomy in the NHS

    Jan 1, 2022, 00:00

  • POSC392 Economic Impact of Multiple Sclerosis from Hospital and Social Security System Perspective in Italy

    Jan 1, 2022, 00:00

  • POSB326 Organizational Assessment of US GI Endoscopy Units

    Jan 1, 2022, 00:00

  • POSA422 Preferences for Person-Centred Care Among People with Dementia in Comparison to Physician's Judgments: Study Protocol for the Predemcare Study

    Jan 1, 2022, 00:00

  • POSC167 A Meta-Analysis and Cost-Minimization Analysis of Oxaliplatin-Based Chemotherapy Versus Irinotecan-Based Chemotherapy with Targeted Molecular Agents in the First-Line Treatment of Metastatic Advanced Colorectal Cancer in China

    Jan 1, 2022, 00:00

  • POSB210 Waiting for a Better Option: Assessing the Likelihood of Gene Therapy Warehousing

    Jan 1, 2022, 00:00

  • POSC231 Variability Drivers of Treatment Costs in Hospitals: A Systematic Review

    Jan 1, 2022, 00:00

  • POSC165 Cost-Effectiveness Analysis of Free Anti-Hypertensive Medicines on Blood Pressure Among HIV Positive Patients at IDI

    Jan 1, 2022, 00:00

  • POSB406 30-Days Cardiovascular In-Hospital Mortality After Heart Valve Intervention: A Real-World Data Analysis in Italy

    Jan 1, 2022, 00:00

  • POSB35 Systematic Literature Review of the Epidemiology, Patient Characteristics, Treatments, Clinical, and Economic Outcomes Associated with Psoriasis in China and Taiwan

    Jan 1, 2022, 00:00

  • POSC357 Economic Burden of Informal Care and Productivity Loss Due to Caring for Individuals with Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency: An Analysis for the US

    Jan 1, 2022, 00:00

  • POSB260 Comparative Success Rates of Immuno-Oncology vs. Other Cancer Treatments Appraised by NICE in the UK, 2011-2020

    Jan 1, 2022, 00:00

  • POSC216 How Should Public Health Recommendations Address LP(A), a Causative Risk Factor for Cardiovascular Disease (CVD)?

    Jan 1, 2022, 00:00

  • POSB393 Profile of Patients with Type 1 or Type 2 Diabetes Treated with Insulin Lispro 100 Units/ML Junior Kwikpen in Routine Clinical Practice in Spain

    Jan 1, 2022, 00:00

  • P38 Sufficient Uptake of Highly Specialised Technologies?

    Jan 1, 2022, 00:00

  • POSC5 Adjusting for Subsequent Therapies in the Tourmaline-MM1 Study Shows Clinically Meaningful Improvement in Overall Survival with Ixazomib in Combination with Lenalidomide and Dexamethasone (IXA+LEN+DEX) Compared to LEN+DEX

    Jan 1, 2022, 00:00

  • POSB74 Belantamab Mafodotin as the First-in-Class Anti-BCMA Treatment for Relapsed/Refractory Multiple Myeloma: A Budget Impact and Cost-Effectiveness Analysis

    Jan 1, 2022, 00:00

  • POSB400 Real World Treatment Patterns and Clinical Outcomes Associated with Palbociclib Combination Therapy across Europe, North and South America, and ASIA: A Pooled Analysis from the IRIS Study

    Jan 1, 2022, 00:00

  • POSA202 Occurrence of Cardiovascular-Related Hospitalization and Emergency Department (ED) Visits for Men with Prostate Cancer Initiating Systemic Androgen Deprivation Therapy (ADT) in the United States

    Jan 1, 2022, 00:00

  • POSB396 Identification of Risk Factors Associated with ICU Admission in COVID-19 Patients

    Jan 1, 2022, 00:00

  • POSB67 Cost-of-Illness for Invasive Meningococcal Disease Caused By Serogroup B Neisseria Meningitidis (MENB) in the Netherlands

    Jan 1, 2022, 00:00

  • POSA421 Two Sensitization Methods: to Enhance Participant Engagement During the Conduct on Online Discrete Choice Experiments: A Case Study

    Jan 1, 2022, 00:00

  • POSA381 Health State Utility Values for Metastatic Pancreatic Cancer in Japan, Based on the Vignette-Based Approach

    Jan 1, 2022, 00:00

  • POSA418 Real-World Patterns of Biomarker Testing in Metastatic Non-Squamous Non-Small Cell Lung Cancer

    Jan 1, 2022, 00:00

  • POSA374 Lingual Adaption of a Questionnaire Assessing Risk Factors Associated with Medication-Related Non-Adheren The Chinese Adherence Barriers Questionnaire (ABQ)

    Jan 1, 2022, 00:00

  • POSB170 Economic Burden of Depression with Concurrent Anxiety in a General Population of US Adults Based on National Health and Wellness Survey (NHWS)

    Jan 1, 2022, 00:00

  • POSA364 Inequity in Health-Related Quality of Life Among Chinese Patients with Hip Fracture

    Jan 1, 2022, 00:00

  • POSC320 EQ-5D Utility Estimates from the Caspian Trial of Durvalumab + Carboplatin/Cisplatin + Etoposide vs. Carboplatin/Cisplatin + Etoposide in First Line Extensive Stage Small Cell Lung Cancer (ES-SCLC)

    Jan 1, 2022, 00:00

  • POSA396 Work Productivity in Patients with Metastatic Breast Cancer: A Retrospective Analysis of Claims Data in the U.S.

    Jan 1, 2022, 00:00

  • P55 Excess Annual Hospital Costs Due to Cardiovascular Events in a Contemporary UK Population to Inform Health Technology Assessments

    Jan 1, 2022, 00:00

  • POSA424 Challenges of COVID-19 Research: Results from a Systematic Literature Review on COVID-19 and Asthma or COPD

    Jan 1, 2022, 00:00

  • POSB117 Analysis of Direct Medical Costs in Adult Patients with Sickle Cell Disease in Colombia

    Jan 1, 2022, 00:00

  • POSB47 Hospital Management and Costs of Unresectable/Locally Advanced or Metastatic Esophageal Cancer in France (Occasion Study)

    Jan 1, 2022, 00:00

  • POSC369 Identification and Assessment of Appropriateness and Safety of Off-Label Use of Corticosteroids in a Tertiary Care Hospital, an Observational Study.

    Jan 1, 2022, 00:00

  • POSC385 Where Are We in Understanding the Cost of Alzheimer’s Disease in Spain?

    Jan 1, 2022, 00:00

  • POSB42 The Health-Economic Evaluation of Risdiplam in Patients with Spinal Muscular Atrophy

    Jan 1, 2022, 00:00

  • POSA157 Clinical Profile and Economic Burden of ANCA-Associated Vasculitis: A Real-World Study Among the Italian Population

    Jan 1, 2022, 00:00

  • POSB283 Approaches for Cost-Effectiveness Analyses in Adjuvant Oncology Indications and Their Acceptability By HTA Authorities

    Jan 1, 2022, 00:00

  • POSA379 Differences in Cancer Treatment Preferences Among Oncologists, Patients and Family Members: A Discrete Choice Experiment

    Jan 1, 2022, 00:00

  • POSB285 Five Identified Hurdles Associated with Surrogate Endpoint Validation

    Jan 1, 2022, 00:00

  • POSA385 Define the European Subjects in Good Health According to Their Vitality Score Based on the National Health and Wellness Survey (NHWS)

    Jan 1, 2022, 00:00

  • POSC68 Cost-Effectiveness Analysis of Community-Based HIV Care Strategies in Mali

    Jan 1, 2022, 00:00

  • POSC79 Hospital Costs Associated with Cataract, Glaucoma, Vitreoretinal, and Laser Refractive Surgeries in Europe: A Comprehensive Literature Review

    Jan 1, 2022, 00:00

  • P74 Treatment Patterns and Outcomes in Patients with Acute Myeloid Leukaemia (AML) in England: A Cancer Analysis System (CAS) Registry Retrospective Cohort Study

    Jan 1, 2022, 00:00

  • POSA45 Impact of Nonadherence to DOACs Among Patients with Non-Valvular Atrial Fibrillation in Sweden: Results from a Real-World Cost-Utility Analysis

    Jan 1, 2022, 00:00

  • P30 Potential Impacts of the New MHRA Policy for Biosimilar Approval for the Industry and Patients

    Jan 1, 2022, 00:00

  • P6 Projecting COVID-19 Hospitalizations and Deaths Under Scenarios of Vaccination in Jefferson County, Kentucky

    Jan 1, 2022, 00:00

  • POSC335 Impact of Physical Functioning of Postmenopausal Women with Osteoporosis on Depression and Quality of Life

    Jan 1, 2022, 00:00

  • POSB155 A Systematic Literature Review of the Economic Burden of Triple Therapy for Moderate to Severe COPD

    Jan 1, 2022, 00:00

  • POSA21 An In-Hospital Study to Trace the Risk Factors Associated with Adverse Drug Reactions during the Second Wave of COVID-19 in a Secondary Care Hospital in India

    Jan 1, 2022, 00:00

  • POSC16 Evaluating the Knowledge and Practice Regarding Foot Care in Diabetes Mellitus Patients Visiting a Tertiary Care Hospital of South India

    Jan 1, 2022, 00:00

  • POSC139 Treatment Patterns, Survival, and Healthcare Resource Use of Patients With Advanced Merkel Cell Carcinoma in England from 2013-2018: Results of a Longitudinal Observational Cohort Study

    Jan 1, 2022, 00:00

  • Assessment of Medical Expenditure for Patients With Breast Cancer in China: Evidence From Current Curative Expenditure by System of Health Accounts 2011

    Jan 1, 2022, 00:00

  • POSA267 How Does Stakeholder Consultation Inform the Development of NICE Clinical Guidelines? The Example of Atrial Fibrillation: Diagnosis and Management

    Jan 1, 2022, 00:00

  • POSC395 Pharmacoeconomic Analysis of rFVIIa Versus PCC in the Treatment of Minor-to-Moderate Bleeds in Hemophilia Patients with Inhibitors in China

    Jan 1, 2022, 00:00

  • Informing the Decision-Making Process in Real Time

    Jan 1, 2022, 00:00

  • POSB427 Are Cancer Trials That Describe Themselves As Pragmatic Actually Pragmatic? Insights from a Systematic Review

    Jan 1, 2022, 00:00

  • POSC63 Cost-Effectiveness of Non-Statin Lipid-Modifying Agents for Primary and Secondary Prevention of Cardiovascular Disease Among Patients with Type 2 Diabetes Mellitus: A Systematic Review

    Jan 1, 2022, 00:00

  • Development and Measurement of Health Utilities

    Jan 1, 2022, 00:00

  • POSC334 Repeatability of the Ground Reaction Force During Stairs Claiming

    Jan 1, 2022, 00:00

  • POSC261 How Was the Societal Perspective Addressed in HTA Decisions About Alzheimer's Disease?

    Jan 1, 2022, 00:00

  • POSB176 Epidemiological Disease Burden of Non-Insulin-Dependent Diabetes with Ophthalmic Complications Based on Routinely Collected Health Insurance Claims Data

    Jan 1, 2022, 00:00

  • POSA282 Oncology Drugs without Phase III Data: Comparison of Reimbursement Recommendations Issued by the Canadian Agency for Drugs and Technologies in Health (CADTH), and the National Institute for Health and Care Excellence (NICE)

    Jan 1, 2022, 00:00

  • POSB265 Use of UK Early Access Data to Inform NICE Technology Appraisals

    Jan 1, 2022, 00:00

  • POSB401 Economic Impact of Innovative Drugs for Multiple Sclerosis: A Real-World Data Analysis

    Jan 1, 2022, 00:00

  • POSA380 Qualitative Development of Surveys to Assess Real-World Patient and Caregiver Perspectives of Atypical Hemolytic Uremic Syndrome Treatment Preferences and Impact

    Jan 1, 2022, 00:00

  • POSB320 Matching-Adjusted Indirect Comparison of Guselkumab Versus Risankizumab in Patients with Moderate-to-Severe Plaque Psoriasis: Change in Baseline PASI from Week 4-40

    Jan 1, 2022, 00:00

  • POSC220 Understanding Value Drivers of European Payers' Evaluation of Products That Combine Pharmaceuticals, Medical Technology and Digital Health − Is a New Approach Needed?

    Jan 1, 2022, 00:00

  • POSC103 Pneumococcal Vaccination with 13-Valent Polysaccharide Conjugate Vaccine for Older Adults with Chronic Conditions: Budget Impact Analysis in Colombia

    Jan 1, 2022, 00:00

  • POSA136 What Are the Benefits of Treatment of Familial Hypercholesterolaemia? A Cost-Effectiveness Model Based on Real-World Data Considering Cholesterol Burden

    Jan 1, 2022, 00:00

  • POSB303 Systematic Review of Probabilistic Sensitivity Analysis Methods in Microsimulation of Chronic Diseases

    Jan 1, 2022, 00:00

  • POSB31 Effects of Valbenazine on Tardive Dyskinesia After Treatment Withdrawal

    Jan 1, 2022, 00:00

  • POSC112 The Effect of the Drug Life Cycle Price on Cost-Effectiveness Results: A Real-World Data Analysis

    Jan 1, 2022, 00:00

  • POSA84 Budget Impact of Larotrectinib for NTRK Fusion Positive Solid Tumors in Greece

    Jan 1, 2022, 00:00

  • POSC375 Digital Data Collection to Measure the Impact of Myasthenia Gravis on Patients' Quality of Life in the Real World: Report at Baseline

    Jan 1, 2022, 00:00

  • POSB216 Unequal Utilization of CDK 4/6 Inhibitors in Sweden

    Jan 1, 2022, 00:00

  • POSC86 Annual Health Insurance Treatment Cost of Senile Cataract Based on Routinely Collected Health Care Financing Data

    Jan 1, 2022, 00:00

  • POSB314 Method of Predicting Serotype Specific Effectiveness Against Invasive Pneumococcal Disease for Pneumococcal Conjugate Vaccines in Infant Population

    Jan 1, 2022, 00:00

  • POSB217 Is the Gene Therapy Revolution Sustainable and Affordable?

    Jan 1, 2022, 00:00

  • POSB353 Quality of Life and Symptom Burden of Paroxysmal Nocturnal Hemoglobinuria Among Patients Receiving C5 Inhibitors in the United States and Europe

    Jan 1, 2022, 00:00

  • POSA77 Radiofrequency-Based Renal Denervation for Treatment-Resistant Hypertension in Italy: A Budget Impact Analysis

    Jan 1, 2022, 00:00

  • POSB388 Cultural Differences in Self-Report Response Styles: An Examination of Patients with Migraine in the National Health and Wellness Survey

    Jan 1, 2022, 00:00

  • POSB403 Reimbursed Cost for Monoclonal Antibodies in Bulgaria: A Case with Adalimumab and Pembrolizumab

    Jan 1, 2022, 00:00

  • POSC226 Perceptions of the Roles and Impact of Clinical Pharmacists By Nigerian Students in Health-Related Disciplines

    Jan 1, 2022, 00:00

  • POSB102 Systematic Literature Review on Cost-Effectiveness and Budget Impact Analysis of Robotic-Assisted Hysterectomy (RAH) for Benign and Malignant Gynecological Conditions

    Jan 1, 2022, 00:00

  • POSB164 Indirect Costs in Heart Failure in Turkey: A Delphi Panel Based Analysis in Relation to Nyha Classes

    Jan 1, 2022, 00:00

  • POSA78 Real-World Assessment of Healthcare Resource Utilisation and Direct Medical Costs in Patients with COPD Receiving LAMA/LABA Therapy in England

    Jan 1, 2022, 00:00

  • POSA412 Using French National Healthcare Databases (SNDS) to Estimate Economic Burden of Diseases: A Literature Review

    Jan 1, 2022, 00:00

  • POSC331 Pilot Investigation of the Short-Term Quality of Life and Socio-Demographic Factors of Patients Underwent Total Hip Arthroplasty in Hungary

    Jan 1, 2022, 00:00

  • POSC22 Demographics and Clinical DATA of a Real World Cohort of Multiple Sclerosis Patients Being Treated with Interferon Beta-1A SC in Portugal

    Jan 1, 2022, 00:00

  • POSB301 Development of a Sequencing Model Using Patient-Level Data to Optimize Patient Outcomes in Multiple Myeloma

    Jan 1, 2022, 00:00

  • POSA139 Measuring Productivity Loss in Early-Stage Relapsing-Remitting Multiple Sclerosis

    Jan 1, 2022, 00:00

  • POSA231 Pain Therapy with Spinal Cord Stimulation (SCS): Patient Characteristics and Healthcare Cost Implications Comparing Early and Late Therapy Start

    Jan 1, 2022, 00:00

  • POSB362 Measuring Patient Preferences: Comparison of Five Discrete Choice Modeling Methods

    Jan 1, 2022, 00:00

  • POSC88 Annual Health Insurance Treatment Cost of Other Cataract Based on Routinely Collected Health Care Financing Data

    Jan 1, 2022, 00:00

  • POSB318 Evaluation of Asynchronous Online Focus Groups for Use in Qualitative Studies Around Patient Experience Data

    Jan 1, 2022, 00:00

  • POSB86 Adjusting Utility Values to Reflect Population Ageing in Cost-Utility Analyses: A Targeted Literature Review

    Jan 1, 2022, 00:00

  • POSB90 Healthcare Resource Utilization and Costs in Adult Patients with Spasticity: A Matched Cohort Analysis

    Jan 1, 2022, 00:00

  • POSC244 Racial Disparities in Healthcare Utilization Outcomes Among Patients with Duchenne Muscular Dystrophy

    Jan 1, 2022, 00:00

  • POSA91 Annual Health Insurance Treatment Cost of Hypertensive Heart Disease with Heart Failure Based on Routinely Collected Financing Data

    Jan 1, 2022, 00:00

  • POSC191 Group Based Trajectory Models to Identify Adherence Pattern to Sodium Glucose Cotransporter 2 Inhibitors Among Type 2 Diabetes Patients

    Jan 1, 2022, 00:00

  • POSA240 Comparative Analysis of Pricing and Reimbursement Policies and Methods: for Prevention and Control of Diseases Caused By HIV Infections in the United Kingdom, Germany, France, Italy, Spain, and Bulgaria

    Jan 1, 2022, 00:00

  • POSB381 Time Trade-Off Utility in Adult Patients with Atopic Dermatitis

    Jan 1, 2022, 00:00

  • POSB68 Inside CKD: Projecting the Economic Burden of Chronic Kidney Disease Using Patient-Level Microsimulation

    Jan 1, 2022, 00:00

  • POSA218 Hospital Exemptions for Atmps: Friend or Foe for Pharma?

    Jan 1, 2022, 00:00

  • POSA68 Cost Minimization Analysis of Fixed-Dose Triple Therapy with Budesonide/Glycopyrronium/Formoterol Fumarate Versus Open Triple Therapy for Moderate-to-Very Severe COPD in the United Kingdom

    Jan 1, 2022, 00:00

  • POSB175 Epidemiological Disease Burden of Non-Insulin-Dependent Diabetes with Renal Complications Based on Routinely Collected Health Insurance Claims Data

    Jan 1, 2022, 00:00

  • POSC85 Annual Health Insurance Treatment Cost of Congestive Heart Failure Based on Routinely Collected Financing Data

    Jan 1, 2022, 00:00

  • POSB197 Impact of Immune Checkpoint Inhibitors (ICIS) on the Management of Advanced Non-Small Cell Lung Cancer (NSCLC) in Real-World Practice at Karolinska University Hospital, Stockholm between 2012 and 2018

    Jan 1, 2022, 00:00

  • POSB149 Health Impact and Cost-Effectiveness Analysis of 9-Valent Versus Bivalent HPV National Immunization Strategies in Singapore

    Jan 1, 2022, 00:00

  • POSA227 Assessment of the Pharmacoeconomic and Pharmacoepidemiological Consequences of the Adoption of the Clinical Decision Support System (CDSS) Components in a Surgical Hospital Using the ACT / DDD Methodology

    Jan 1, 2022, 00:00

  • POSA241 Diabetic Macular Edema Patients Treated with ANTI-VEGF Intravitreal Injections in Portugal: An Administrative Database Study from 2013 to 2018

    Jan 1, 2022, 00:00

  • POSC43 Healthcare Resource Use and Activities of Daily Living Status Among Adult Patients with Spinal Muscular Atrophy: A Natural History Multicountry Chart Review Study

    Jan 1, 2022, 00:00

  • POSC409 Demographic Characteristics and Initial Diagnostic Staging of Patients with Breast Cancer Across Large Community Health Systems in the US

    Jan 1, 2022, 00:00

  • POSB12 Association Between Remdesivir Treatment and In-Hospital All-Cause Mortality Among Patients Hospitalized with COVID-19

    Jan 1, 2022, 00:00

  • P76 Federated Analysis of Multi-Centric Real-World Data: A Feasibility Study

    Jan 1, 2022, 00:00

  • POSC342 Mapping Health Utilities for Patients with Cerebral Adrenoleukodystrophy Using Trial-Based Pedsql Scores

    Jan 1, 2022, 00:00

  • POSC312 A Methodological Approach to Assess the Economic Value of Difelikefalin to Treat Chronic Kidney Disease Associated Pruritus (CKD-AP)

    Jan 1, 2022, 00:00

  • POSA371 Barriers and Expectations for Patients in Post-Osteoporotic Fractures Care in Fran The Effel Study

    Jan 1, 2022, 00:00

  • POSB391 Patient-Perceived Burden of Pain in Uterine Fibroids: Results from a Prospective Real-World Evidence Study in the USA

    Jan 1, 2022, 00:00

  • POSC361 Evaluating the Use of Treatment Preference Methods: in Oncology Clinical Trials

    Jan 1, 2022, 00:00

  • POSB44 Drivers of Value-Based Price (VBP) for a Multi-Cancer Early Detection (MCED) Test

    Jan 1, 2022, 00:00

  • POSB88 Dermatologist-Assessed Direct Medical Costs of Adult and Adolescent Patients with Atopic Dermatitis in China

    Jan 1, 2022, 00:00

  • POSA96 The Economic Burden of Thromboembolic Events (TE) Among Patients with Inflammatory Bowel Disease (IBD)

    Jan 1, 2022, 00:00

  • POSC38 Study on the Management of Carriers in Hereditary Transthyretin Amyloidosis (EMPATIA): Economic and Healthcare Resource Utilization in Spain

    Jan 1, 2022, 00:00

  • POSC4 Modeling Health-Related Outcomes With Avelumab as a First-Line Maintenance Treatment Following Chemotherapy vs. Best Supportive Care (BSC) for Patients With Locally Advanced or Metastatic Urothelial Cancer in the UK

    Jan 1, 2022, 00:00

  • POSC157 Treatment of Moderate-to-Severe Active Psoriatic Arthritis: Cost-Effectiveness Analysis and Budget Impact Analysis of Biologics and Targeted Therapies Approved in the Russian Federation

    Jan 1, 2022, 00:00

  • P42 Comparison of Estimation Methods for Single-Arm Trials in Rare Diseases with Historical Control Groups

    Jan 1, 2022, 00:00

  • POSA171 Incidence of Guillian-Barré Syndrome in Europe: A Targeted Literature Review

    Jan 1, 2022, 00:00

  • POSB126 Inpatient Burden of Influenza in the Elderly in Germany

    Jan 1, 2022, 00:00

  • POSC126 Budget Impact Analysis of Adopting Sodium-Glucose Cotransporter-2 Inhibitor for Treatment of Type 2 Diabetes Mellitus in Ministry of Health Malaysia

    Jan 1, 2022, 00:00

  • POSB229 Organizational Assessment of Duodenoscopes in US Hospitals

    Jan 1, 2022, 00:00

  • POSC28 Systematic Literature Review of Second-LINE Treatments for SMALL-Cell LUNG Cancer

    Jan 1, 2022, 00:00

  • P14 Exploring the Potential for EHR-Derived Real-World Data to Reduce Uncertainty in HTA Decision-Making: A Case Study of Long-Term Survival Outcomes

    Jan 1, 2022, 00:00

  • POSA43 Pharmacoeconomic Analysis of the Use of Antiretroviral Drugs Based on Local Data of Real Clinical Practice and State Drug Provision of HIV-Infected People in the Russian Federation

    Jan 1, 2022, 00:00

  • POSC9 Early Response in the Treatment of Invasive Candida Disease, Length of Stay on the Intensive Care Unit and Projected Costs with Once-Weekly Rezafungin Antifungal Therapy

    Jan 1, 2022, 00:00

  • POSC78 Is There an Optimal Way to Estimate Healthcare Resource Use?

    Jan 1, 2022, 00:00

  • POSA85 Annual Health Insurance Treatment Cost of Non-Insulin-Dependent Diabetes with Coma Based on Routinely Collected Financing Data

    Jan 1, 2022, 00:00

  • Using Real World Evidence to Predict Risks of Adverse Outcomes and Disease Progression

    Jan 1, 2022, 00:00

  • POSA262 The Use of Akaike Information Criterion and Bayesian Information Criterion Rules of Thumb in Nice Oncology Appraisals: A Targeted Review

    Jan 1, 2022, 00:00

  • POSB5 Real-World Patterns of Treatment and Dose Modification with CDKI 4/6 for Advanced Breast Cancer in Portugal

    Jan 1, 2022, 00:00

  • POSB255 Enough with the Madness! Hydroxychloroquine Is NOT a Treatment for COVID-19.

    Jan 1, 2022, 00:00

  • POSB279 A Comparison Study of Prices and Market Access Delays for ATUC Drugs in France Versus EU4 UK

    Jan 1, 2022, 00:00

  • POSA61 Incremental Cost per Relapse Avoided of Ozanimod Compared with First-Line Disease-Modifying Therapies for Relapsing Forms of Multiple Sclerosis

    Jan 1, 2022, 00:00

  • POSC207 Variables Affecting Pricing of Orphan Drugs: The Italian Case

    Jan 1, 2022, 00:00

  • POSB252 Highly Specialised Trials: Has Eligibility for NICE Highly Specialised Technology Appraisals Become More Strict?

    Jan 1, 2022, 00:00

  • P47 A Bayesian Hierarchical Mixture Cure Modelling (MCM) Framework for the Joint Utilization of Progression Free Survival (PFS) and Overall Survival (OS) in Estimating Long-Term Survivorship Rates in Previously Untreated Metastatic Melanoma ...

    Jan 1, 2022, 00:00

  • Impact of the COVID-19 Pandemic: Investigations in Populations of Interest

    Jan 1, 2022, 00:00

  • POSB144 Evaluation of the Economic Impact of Increasing Influenza VCR for Diabetes Mellitus Type 2 Population in Panama

    Jan 1, 2022, 00:00

  • POSC8 Burden of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency in Italian Patients from Symptomatology and Motor Development Perspective

    Jan 1, 2022, 00:00

  • POSC109 Cost-Effectiveness Analysis of Reference Recombinant Human Follicle-Stimulating Hormone ALFA (R-HFSH-ALFA) and Urinary Highly Purified Menopausal Gonadotropin (HMG-HP) Based on DATA from a Large German Registry

    Jan 1, 2022, 00:00

  • POSA386 Costs of Hospital Care and Productivity Loss Due to Sickle Cell Disease in Sweden: A Retrospective Study

    Jan 1, 2022, 00:00

  • POSB153 Health Economic Evaluation of Different Treatment Modalities for Extracorporeal Photopheresis: Can New Alternatives Generate Health Economic Value?

    Jan 1, 2022, 00:00

  • POSB71 A Budget Impact Analysis (BIA) of the Dyna Form Mercury Advance Smartcare® Mattress to Prevent Pressure Ulcers in the Austrian Inpatient Setting

    Jan 1, 2022, 00:00

  • POSB281 Do HTA Bodies Have an Issue with Diversity?

    Jan 1, 2022, 00:00

  • POSB97 Cost-Consequence Model of Using Gene Expression Tests in Patients with Early Breast Cancer in the Netherlands

    Jan 1, 2022, 00:00

  • POSA65 Utilization-Based Managed Entry Agreements: Is There a Future for These Arrangements Across the EU4?

    Jan 1, 2022, 00:00

  • POSB95 The Cost-Effectiveness of Newborn Screening for Metachromatic Leukodystrophy (MLD) in the UK

    Jan 1, 2022, 00:00

  • POSB145 Budget Impact of Pegcetacoplan, a Complement C3 Inhibitor, for the Treatment of Paroxysmal Nocturnal Hemoglobinuria in US Adults

    Jan 1, 2022, 00:00

  • POSB215 Monetary Value of Life Years in Full Capability Applying the Well-Being Valuation Approach in Hungary

    Jan 1, 2022, 00:00

  • POSC267 Atezolizumab + Bevacizumab Versus Other Systemic Therapies for the First Line Treatment of Unresectable Hepatocellular Carcinoma: A Systematic Literature Review and Indirect Treatment Comparison

    Jan 1, 2022, 00:00

  • POSA329 Fabry Disease: Symptom Burden, Health-Related Quality of Life Burden and Treatment Satisfaction

    Jan 1, 2022, 00:00

  • POSB358 Health State Utilities Associated with Weight Loss in Type 2 Diabetes and Obesity

    Jan 1, 2022, 00:00

  • POSB273 Recommendations and Health Technology Assessment (HTA) Landscape Evaluation Study for Pediatric Pneumococcal Conjugate Vaccine (PCV) in Europe: A Systematic Literature Review

    Jan 1, 2022, 00:00

  • POSC257 Radiopharmaceutical Treatments and HTA: The Case of [177lu]-DOTATATE

    Jan 1, 2022, 00:00

  • POSB152 The Health and Budget Impact of Safer Lower Dose Direct Oral Anticoagulant Formulations in Non-Valvular Atrial Fibrillation Patients

    Jan 1, 2022, 00:00

  • POSC161 Cost-Consequence Analysis of Rosuvastatin Versus Atorvastatin in the Spanish Setting

    Jan 1, 2022, 00:00

  • POSB390 Characterisation of the Management Pathway for Muscle-Invasive Urothelial Carcinoma (MIUC) from Physician Perspectives in France, Germany, Italy, Spain, UK (EU5), US, Canada, China, and Japan

    Jan 1, 2022, 00:00

  • POSB371 Patient and Physician Response Scale Preferences for Clinical Outcome Assessments in Sjogren's: A Qualitative Comparison of Visual Analogue Scale, Numerical Rating Scale, and Likert Scale Response Options

    Jan 1, 2022, 00:00

  • POSC132 A Mapping Exercise and Temporal Extrapolation of the WOMAC Index for Adults with X-Linked Hypophosphataemia (XLH) Treated with Burosumab

    Jan 1, 2022, 00:00

  • POSB178 Geographical Inequalities in Coronavirus (SARS-COV-2) Mortality in Europe

    Jan 1, 2022, 00:00

  • P59 To What Extent Is EQ-5D Used as a Tool for Clinical Outcome Assessment?

    Jan 1, 2022, 00:00

  • POSC288 Evidence Requirements in the Regulatory and Reimbursement Processes of Digital Therapeutics: Insights from the US, EU4 and UK

    Jan 1, 2022, 00:00

  • POSA300 Combining Clinical Trial and Real-World Evidence Data in the Assessment of Public Health Impact in HTA Evaluations

    Jan 1, 2022, 00:00

  • POSB334 Examination of Physical Activity Among High School Students Specialized in Physical Education and Mathematics

    Jan 1, 2022, 00:00

  • POSC100 Healthcare Resource Utilization and Costs in Pediatric Cerebral Palsy Patients with Spasticity: A Matched Cohort Analysis

    Jan 1, 2022, 00:00

  • POSB125 The Impact of Discounting on the Cost Effectiveness of Tisagenlecleucel for Relapsed/Refractory Acute Lymphoblastic Leukaemia

    Jan 1, 2022, 00:00

  • POSC77 Incorporating Possibility of Cure into Cost Utility Analysis for Nivolumab in Adjuvant Treatment of Resected Stage III/IV Melanoma in France

    Jan 1, 2022, 00:00

  • POSA154 A Comparison of the Costs of Atrial Fibrillation Ablation Using Radiofrequency and Cryobaloon Technologies in the United Kingdom and Italy

    Jan 1, 2022, 00:00

  • POSA297 Preferences for Hemophilia Treatments in Canada: A Discrete Choice Experiment (DCE)

    Jan 1, 2022, 00:00

  • POSC313 Network Meta-Interpolation; A Fast, Novel NMA Approach Accounting for Effect Modification

    Jan 1, 2022, 00:00

  • POSA301 A Review of Pharmaceutical Benefits Advisory Committee (PBAC) Public Summary Documents to Investigate the Use of Child-Specific Utility Measures in Decision Making in Australia

    Jan 1, 2022, 00:00

  • POSC249 Analysis of Pharmacoutilization of Biological Drugs in Psoriatic Arthritis Patients: A Real World Retrospective Study Among Italian Population

    Jan 1, 2022, 00:00

  • POSA413 Analyze the Treatment Pattern and Medical Cost for Acute Myeloid Leukemia: A Retrospective Claims Data Analysis in Japan

    Jan 1, 2022, 00:00

  • POSA73 The Cost-Related Advantages of Implementing Single-Use Bronchoscopes in a Bronchoscopy Suite Setting: A Micro-Costing Evaluation

    Jan 1, 2022, 00:00

  • POSA204 Disease Burden of Iga Nephropathy in China

    Jan 1, 2022, 00:00

  • POSC281 Critiques of Survival Analysis Methods Used in Immuno-Oncology Appraisals Assessed by NICE in the UK, 2011-2020

    Jan 1, 2022, 00:00
  • «
  • 31 (current)
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • »